Cabaletta Bio
CABA
108 hedge funds and large institutions have $228M invested in Cabaletta Bio in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 13 closing their positions.
2,362% more call options, than puts
Call options by funds: $9.78M | Put options by funds: $397K
108% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 13
36% more capital invested
Capital invested by funds: $167M → $228M (+$60.6M)
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
14% more funds holding
Funds holding: 95 → 108 (+13)
3.14% less ownership
Funds ownership: 79.2% → 76.06% (-3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.79M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.45M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$3.39M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$3.39M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Superstring Capital Management
New York
|
-$3.3M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.27M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.81M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$1.2M |
| 5 |
Jane Street
New York
|
-$1.15M |
CABA Hedge Fund Activity: Q1 2026 in Review
108 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q1 2026, worth a combined $228M — up 36% from $167M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CABA positions and 13 closed out — a net gain of 14 holders — while 32 added to existing stakes and 27 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.79M. The largest seller was Superstring Capital Management, cutting an estimated $3.3M.
- 108 institutional investors held Cabaletta Bio (CABA) as of Q1 2026, up from 95 in Q4 2025.
- Funds reported $228M of Cabaletta Bio stock for Q1 2026, up 36% quarter-over-quarter.
- 27 funds opened new Cabaletta Bio positions in Q1 2026 and 13 closed out, a net change of +14 holders.
- The largest Cabaletta Bio buyer in Q1 2026 was Millennium Management, an estimated $8.79M added.
- The largest Cabaletta Bio seller in Q1 2026 was Superstring Capital Management, an estimated $3.3M sold.
Based on aggregated 13F filings for Q1 2026.